Conformis (CFMS) Stock Price, News & Analysis

Company Overview

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Brazil, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.

Key Stats

• Today's Range: $2.25 to $2.27
• 50-Day Range: $2.22 to $2.26
• 52-Week Range: $1.05 to $7.25
• Volume: 7,000 shs
• Average Volume: 99,585 shs
• Market Capitalization: $17.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CFMS Stock Analysis - Frequently Asked Questions

How were Conformis' earnings last quarter?

Conformis, Inc. (NASDAQ:CFMS) announced its earnings results on Wednesday, November, 3rd. The medical instruments supplier reported ($1.75) EPS for the quarter, hitting analysts' consensus estimates of ($1.75). The medical instruments supplier earned $14.25 million during the quarter, compared to the consensus estimate of $14.08 million. Conformis had a negative net margin of 72.72% and a negative trailing twelve-month return on equity of 86.46%.
Read the conference call transcript.

When did Conformis' stock split?

Conformis's stock reverse split on Wednesday, November 9th 2022.The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Conformis IPO?

Conformis (CFMS) raised $135 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What other stocks do shareholders of Conformis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Conformis investors own include Meta Platforms (META), Micron Technology (MU), NIO (NIO), NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/03/2021
• Today: 7/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CFMS
• CIK: 1305773
• Web: www.conformis.com
• Phone: (781) 345-9001
• Fax: 781-345-0147
• Employees: 295
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($5.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$50.47 million
• Net Margins: -72.72%
• Pretax Margin: -72.63%
• Return on Equity: -86.46%
• Return on Assets: -47.65%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 5.07
• Quick Ratio: 3.30

Sales & Book Value

• Annual Sales: $57.06 million
• Price / Sales: 0.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.07 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 7,878,000
• Free Float: 7,579,000
• Market Cap: $17.80 million
• Optionable: Not Optionable
• Beta: 1.39